Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Summary

The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.

Timeline

Start

2022-09-08

Primary completion

2023-08-30

Completion

2023-08-30

Outcome

Outcome not reported

Stopped: “The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study.”

Drugs

Indications